Effect of kunxian capsule and leflunomide on IgA nephropathy

• Register: ChiCTR
• Last refreshed on: 26 November 2018
• Main ID: ChiCTR1800019606
• Date of registration: 2018-11-19
• Prospective Registration: Yes
• Primary sponsor: The First Affiliated Hospital of Chengdu Medical College
• Public title: Effect of kunxian capsule and leflunomide on IgA nephropathy
• Scientific title: Effect of kunxian capsule and leflunomide on IgA nephropathy
• Date of first enrolment: 2018-12-01
• Target sample size: 1:20;2:20;
• Recruitment status: Pending
• URL: http://www.chictr.org.cn/showproj.aspx?proj=30728
• Study type: Interventional study
• Study design: Quasi-randomized controlled
• Phase: Post-market

Countries of recruitment

China

Contacts

• Name: FAN JUNMING
• Affiliation: The First Affiliated Hospital of Chengdu Medical College

• Name: ZHENG YUNHENG
• Affiliation: The First Affiliated Hospital of Chengdu Medical College

Key inclusion & exclusion criteria

Inclusion criteria: 1. Renal biopsy proved to be IgA nephropathy;
2. aged 15~75 years old;
3. According to the KDIGO guidelines, patients with IgA nephropathy do not need to use glucocorticoid and immunosuppressive agents;
4. Volunteer for clinical trials and sign informed consent.
Exclusion criteria: 1. Combined with other immune diseases;
2. Allergic to this drug;
3. Acute renal insufficiency;
4. Liver function damage;
5. gestation;
6. receiving other immunosuppressants drug.

Age minimum: 15
Age maximum: 75
Gender: Both

Health Condition(s) or Problem(s) studied

IgA nephropathy

Intervention(s)

1:Kun-Xian Capsule;2:Leflunomide;

Primary Outcome(s)

the 24-hour urinary protein;albumin;creatinine;

Secondary Outcome(s)

ACR;Urine RBC;hemoglobin;

Source(s) of Monetary Support

Project funds

Ethics review

Status: Approved
Approval date: 09/10/2018
Contact:

ZHU WENWEN

[phone]